T1	Participants 52 97	patients with pulmonary arterial hypertension
T2	Participants 172 224	patients with pulmonary arterial hypertension (PAH).
T3	Participants 494 580	randomized patients with PAH to receive placebo or sitaxsentan 50 or 100Â mg once daily
T4	Participants 895 963	98 randomized patients, 61% were WHO functional class II at baseline
T5	Participants 1654 1719	PAH patients who were mostly WHO functional class II at baseline.
